Squamous Cell Carcinoma Treatment Options

The Direct Answer: Treat the Risk, Not Just the Name

Most cutaneous squamous cell carcinomas, shortened to cSCC or simply SCC, are cured with surgery. The challenge is recognizing the smaller group that does not behave like an ordinary surface skin cancer.

A 6-mm, sharply defined SCC on the forearm and a recurrent SCC tracking along a nerve near the ear may share the same diagnosis. They do not share the same danger, margin problem, or treatment plan.

Think of the pathology report as the label on a package and risk assessment as opening the box. The label matters, but it does not tell you everything inside. The best treatment follows the most important feature present, not the most reassuring feature.

What Is Cutaneous Squamous Cell Carcinoma?

cSCC begins in keratinocytes, the cells that form most of the epidermis. Ultraviolet radiation is the leading preventable cause. SCC can appear as a growing scaly patch, thick crust, tender bump, nonhealing sore, or bleeding lesion, but appearance alone cannot establish the diagnosis.^1,2

Most cSCCs remain local and are cured. Unlike basal cell carcinoma, however, SCC has a meaningful ability to enter lymphatic channels, involve nerves, spread to nearby lymph nodes, and occasionally spread to distant organs. That does not mean every SCC is dangerous. It means classification matters.

The first treatment discussion should answer five questions:

1. Is this SCC in situ, confined to the epidermis, or invasive SCC, extending into deeper skin?
2. Is the tumor lower risk, high risk, or very high risk?
3. How will the complete peripheral and deep margin be evaluated?
4. Do nerves or lymph nodes need additional examination?
5. Does the patient's immune status or health change the plan?

The First Decision Is Risk

Current NCCN treatment guidance separates cSCC into low-, high-, and very-high-risk pathways. The highest-risk feature governs the pathway. A tumor does not average its good and bad features together.^1–3

Risk category and stage are related but not interchangeable. NCCN risk groups guide treatment. The Brigham and Women's Hospital system helps estimate prognosis. AJCC-8 staging applies specifically to head-and-neck cSCC. One system should not be substituted for another.^1,3–5

The Biopsy Is a Starting Map

A biopsy proves the diagnosis and can identify depth, differentiation, nerve involvement, and other risk features. It is still a sample. A superficial biopsy may not show the deepest part of the tumor, and a negative edge on a diagnostic biopsy does not prove that the entire cancer has been definitively removed.²

The complete pathology report should be reviewed before treatment. Important words include:

• invasive versus in situ;
• depth or thickness;
• well, moderately, or poorly differentiated;
• perineural invasion;
• lymphovascular invasion;
• invasion beyond fat, cartilage, muscle, or bone;
• recurrence; and
• adenosquamous or sarcomatoid features.^1,2,6

If the biopsy result does not fit the clinical appearance, if a rare subtype is reported, or if a major operation depends on one ambiguous phrase, expert dermatopathology review may change the plan.

Treatment Options at a Glance

When Is Mohs Surgery Usually the Strongest Option?

Mohs micrographic surgery removes the visible tumor with a thin layer of surrounding tissue, maps that layer, examines the complete peripheral and deep margin using en-face sections, and returns only to the mapped area where cancer remains. The surgeon repeats that process until the mapped margin is clear, then plans reconstruction.^1,7

That feedback loop is the Mohs advantage. Standard pathology is excellent at the sections it examines, but routine vertical sections are separated by unexamined intervals. Mohs evaluates the continuous mapped margin surface. The difference becomes more important as the cost of residual tumor rises.⁷

Mohs is generally the strongest local treatment when one or more of these apply:

• the tumor is on the head, neck, hand, foot, genital skin, or another tissue-sensitive site;
• clinical borders are indistinct;
• the cancer is recurrent or persistent;
• pathology is poorly differentiated, adenosquamous, sarcomatoid, deeply invasive, or nerve-involved;
• the patient is meaningfully immunosuppressed;
• the tumor is large or very high risk;
• prior radiation or scarring obscures the edge; or
• reconstruction should begin only after the complete margin is known.^1,7–10

The strongest modern comparative study

A 2025 multicenter cohort compared Mohs or another form of complete-margin assessment with vertical-section excision in 2,752 NCCN very-high-risk cSCCs treated at 12 sites.⁸

Every major measured outcome favored complete margin assessment. Local recurrence was reduced by 6.6 percentage points. Disease-specific death fell by 2.9 percentage points, from 6.2% to 3.3%, which is an approximately 47% relative reduction.

No randomized Mohs-versus-excision trial exists for cSCC. The evidence is nevertheless coherent: guidelines favor complete-margin methods as risk rises, systematic reviews support better local control with complete assessment, and the largest modern comparative cohort favored Mohs across recurrence, spread, and disease-specific death.^1,8–10

When Is Standard Excision a Good Choice?

Standard excision removes the visible tumor with a planned clinical margin. The specimen is sent to a pathology laboratory, where representative vertical sections are examined. For a primary, well-defined, lower-risk cSCC, it is a sound and highly effective operation.^1,2

Current guidance supports a 4- to 6-mm clinical margin for selected well-defined low-risk cSCC. High- and very-high-risk tumors do not have one universal safe excision margin; their borders and subclinical extension vary too much for a single ruler number.^1,2

Standard excision commonly fits a tumor that is:

• primary rather than recurrent;
• small and well defined;
• not deeply invasive;
• not poorly differentiated;
• not nerve- or vessel-involved;
• on a site where a planned margin can be removed safely; and
• in a patient without a major risk modifier.

If a complex flap or graft is planned for a higher-risk tumor, the surgeon should explain whether reconstruction will wait for margin confirmation. The larger the repair, the more important it is to avoid building it over an uncertain margin.

When Can ED&C Be Appropriate?

Electrodesiccation and curettage, or ED&C, uses a curette to scrape the tumor and electrodesiccation to treat the base. It can be a sensible, efficient treatment for a selected small, primary, lower-risk cSCC on a non-terminal-hair-bearing site.^1,11

ED&C does not provide a histologic margin specimen. Results depend heavily on tumor selection, site, depth, and operator experience. It should not be the default for:

• a recurrent tumor;
• a poorly defined tumor;
• a high-risk facial site;
• terminal hair-bearing skin, where follicular extension can matter;
• poor differentiation or aggressive pathology;
• deep invasion;
• nerve involvement; or
• immune suppression that materially raises concern.^1,11

The point is not that ED&C is weak. It is powerful within its lane. Trouble begins when a narrow low-risk method is stretched to solve a high-risk margin problem.

SCC In Situ Is a Different Treatment Fork

SCC in situ, also called Bowen disease, is confined to the epidermis. Because it has not invaded deeper skin, the treatment menu can include excision, ED&C, selected topical therapy such as 5-fluorouracil or imiquimod, cryotherapy, or other field-directed treatment depending on site, size, borders, patient health, and diagnostic confidence.¹

Invasive cSCC is a different problem. A cream that can treat selected surface-confined disease should not be presented as an equivalent treatment for an invasive, deeply extending, or high-risk tumor.

Surgery is especially useful when:

• invasion cannot be excluded;
• the lesion is thick or indurated;
• borders are poorly defined;
• the diagnosis is uncertain;
• the site is high risk; or
• knowing the margin matters more than avoiding an operation.

When Radiation Enters the Plan

Radiation is a genuine treatment option when surgery is medically infeasible, is declined after informed discussion, or would cause unacceptable functional harm. It can also be added after surgery in selected tumors with substantial nerve involvement, nodal disease, recurrence, or other locoregional risk.^1,12–15

For an operable high-risk cSCC in a fit patient, radiation should not be described as though it offers the same immediate margin information as Mohs. Radiation treats a field without producing a complete excised margin map. Its treatment course, late tissue effects, and future reconstructive consequences are different.

Evidence for postoperative radiation after clear margins is mixed and mostly retrospective. That means it should be targeted to a specific residual risk rather than added automatically to every high-risk label.^13–15

When Immunotherapy or Drug Treatment Enters the Plan

PD-1 immunotherapy has changed advanced cSCC care. Cemiplimab is a PD-1 blocking antibody, not a PD-L1 drug. It is active in unresectable locally advanced or metastatic cSCC and now also has selected neoadjuvant and adjuvant roles.^16–18

Before surgery: neoadjuvant treatment

In a phase II study of resectable stage II-IV cSCC, neoadjuvant cemiplimab produced a pathologic complete response in 51% of patients. A pathologic complete response means no viable cancer was found in the surgical specimen after drug treatment.¹⁷

That result is important, but it is not a reason to replace straightforward curative surgery with immunotherapy. Neoadjuvant treatment belongs to selected advanced tumors in a coordinated program where the response can alter an otherwise difficult operation.

After surgery and radiation: adjuvant treatment

The C-POST randomized trial studied selected high-risk patients after surgery and postoperative radiation. At 24 months, disease-free survival was 87.1% with cemiplimab and 64.1% with placebo, with a hazard ratio of 0.32.¹⁶

Overall-survival benefit from adjuvant cemiplimab has not yet been established. That is a meaningful outcome boundary, not a reason to minimize the disease-free-survival result.

Why Nerves and Lymph Nodes Matter

Perineural invasion means tumor is present around or within a nerve. Microscopic incidental involvement of a tiny unnamed nerve is not the same as pain, numbness, weakness, radiographic nerve spread, or involvement of a larger named nerve. The latter findings carry greater concern and can change imaging, surgery, radiation, and follow-up.^1,19,20

Lymphovascular invasion means tumor is present in a lymphatic or blood vessel and is an adverse feature.⁶

Higher-risk SCC deserves a deliberate lymph-node examination. Imaging is selective rather than automatic:

• contrast-enhanced CT is commonly used when nodal staging is the main question;
• MRI is preferred when perineural spread is suspected; and
• ultrasound, PET/CT, or other studies can fit specific clinical questions.^1,21

Pain numbness tingling weakness or a new regional lymph node should prompt evaluation beyond the primary skin lesion; these findings do not prove spread but can change imaging nodal assessment or multidisciplinary planning.

Sentinel lymph-node biopsy is not routine standard care for cSCC. Current guidance lists it as a category 2B consideration for selected clinically node-negative very-high-risk tumors.¹

How Immune Suppression Changes Treatment

Organ transplantation, chronic lymphocytic leukemia and other hematologic cancers, stem-cell transplantation, HIV, and immune-modifying medications are not one identical category. They can change SCC incidence, biology, treatment tolerance, and the balance between cancer control and immune function.^1,22,23,34

For an immunosuppressed patient, clinicians should have a lower threshold to:

• verify risk features carefully;
• use complete margin assessment for a concerning tumor;
• examine regional lymph nodes;
• investigate pain, numbness, rapid growth, or recurrence;
• coordinate with oncology, transplant, or prescribing teams; and
• intensify surveillance when the tumor and immune context warrant it.

Across 67 studies of solid-organ transplant recipients, the pooled cSCC standardized incidence ratio was 45.9, although individual estimates ranged from about 5 to over 200 depending on organ, location, era, regimen, and time since transplant.²²

Patients should never stop antirejection or immune-modifying medication on their own. Checkpoint immunotherapy can produce meaningful cSCC responses after transplant, but it can also trigger organ rejection or graft loss. These decisions require the treating specialists together.^24,27,29,30

When Mohs May Not Be Necessary

Mohs is not required for every SCC. A good Mohs surgeon should recognize when a simpler method reliably fits.

Mohs may add little when the tumor is:

• primary;
• small and sharply defined;
• lower risk by location, depth, and pathology;
• on a site where a 4- to 6-mm margin is safe;
• in a patient without major immune or recurrence risk; and
• readily treated by standard excision.

Selected ED&C can be appropriate in an even narrower lower-risk group. Selected SCC in situ may be treated nonsurgically. In a patient with severe competing illness or limited life expectancy, the burden of treatment may outweigh the benefit of treating a genuinely indolent lesion immediately.

The credibility of a Mohs recommendation depends on this boundary. Use Mohs when its map changes the cancer decision—not merely because the procedure exists.

A Practical Decision Framework

Five Common Patient Examples

1. A small, sharply defined SCC on the forearm

If pathology and examination show a primary lower-risk tumor, standard excision may be exactly right. Mohs is not automatically necessary simply because the diagnosis is SCC.

2. A recurrent SCC near the ear

Recurrence, head-and-neck anatomy, possible nerve proximity, and indistinct scarred borders make Mohs the stronger local strategy. The regional lymph nodes and neurologic symptoms also deserve attention.

3. SCC in situ on the trunk

Excision, ED&C, or a selected topical treatment may fit. The deciding questions are whether invasion was adequately excluded, how well defined the lesion is, and whether the patient can complete and tolerate the nonsurgical course.

4. A rapidly growing, poorly differentiated SCC in a transplant recipient

This belongs in a high-intensity pathway: complete margin assessment, deliberate nodal evaluation, coordination with the transplant team, and risk-matched follow-up. A simple destruction procedure would not solve the real problem.

5. A very-high-risk tumor already removed with adverse features

The next discussion may include pathology review, imaging, radiation, and—when the patient matches trial and regulatory criteria—adjuvant cemiplimab. Clear margins can be the beginning of the plan rather than the end.

Questions to Ask Before Choosing Treatment

1. Is this SCC in situ or invasive?
2. Which feature makes it low, high, or very high risk?
3. Is the biopsy deep enough to assess the important features?
4. How will the complete peripheral and deep margin be examined?
5. Would Mohs reduce the chance of leaving tumor behind at this site?
6. Do pain, numbness, weakness, or pathology suggest nerve involvement?
7. Were the regional lymph nodes examined, and is imaging useful?
8. Should reconstruction wait until margins are known?
9. Does immune suppression change treatment or follow-up?
10. Is radiation or PD-1 therapy solving a specific risk that surgery alone does not address?

Standard excision can be an excellent choice for a selected lower-risk tumor, while Mohs can fit when mapped margin information or tissue preservation changes the decision.

Next Steps in the Patient Journey

• Read Low-Risk vs High-Risk Skin Cancer if the risk language is still unclear.
• Compare Mohs Surgery vs Standard Excision when surgery is the likely pathway.
• Continue to Do I Need Mohs Surgery? for an appropriateness framework.
• If Mohs is planned, read What Happens on the Day of Mohs Surgery?
• Use How Will My Skin Cancer Wound Be Repaired? after the cancer-clearance plan is settled.
• Share this guide with your treating dermatologist and ask how your margins will be evaluated.